Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer

Is this drug therapy an effective therapeutic option for HR+/HER2- advanced breast cancer? What benefits might this treatment offer over single-agent chemotherapy?Journal of Clinical Oncology

Source: Medscape Today Headlines - January 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news